Restricting to these high-confidence variants, the DRP decreases below 10% and the drugs with the highest DRPLoF include the anti-cancer drug marimastat (DRPLoF = 8.3%), the anti-ulcer medication sulfacrate (DRPLoF = 8.2%), the anti-flu drug oseltamivir (DRPLoF = 6.0%), which targets human CES1 for activation, and several liptins used for diabetes that inhibit DPP4 (DRPLoF = 5.6%) (Additional file 2: Table S3). The gene discussed is CES1; the disease is cancer.